- Home
- API vs LYEL Comparison
API vs LYEL Comparison
Compare API & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | API | LYEL |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.0M | 320.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | API | LYEL |
|---|---|---|
| Price | $3.98 | $13.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 398.3K | 247.6K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $12.87 | $8,712.13 |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.14 | $9.11 |
| 52 Week High | $5.50 | $45.00 |
Technical Indicators
Market Signals| Indicator | API | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 46.74 |
| Support Level | $3.69 | $11.59 |
| Resistance Level | $4.06 | $14.14 |
| Average True Range (ATR) | 0.20 | 1.39 |
| MACD | -0.01 | 0.31 |
| Stochastic Oscillator | 42.96 | 43.71 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.